The brand name for levosimendan is Uptravi [1].
Are there common misspellings of Uptravi?
Searches for Uptravi may include variations in spelling. Common misspellings could include differences in vowel usage or consonant order, though specific instances are not readily available in public documentation.
What is Uptravi used for?
Uptravi is a medication prescribed to treat adult patients with pulmonary arterial hypertension (PAH) [1]. PAH is a condition characterized by high blood pressure in the arteries of the lungs and the right side of the heart.
How does Uptravi work?
Uptravi, also known as levosimendan, is a calcium sensitizer that works by increasing the heart's sensitivity to calcium. This process leads to vasodilation, meaning it widens blood vessels, and specifically relaxes the smooth muscle in the pulmonary arteries [1]. This relaxation reduces the pressure in the pulmonary arteries, making it easier for the heart to pump blood through the lungs.
When was Uptravi approved?
The U.S. Food and Drug Administration (FDA) approved Uptravi for the treatment of PAH in adults on March 30, 2017 [2].
What are the side effects of Uptravi?
Common side effects associated with Uptravi treatment include headache, nausea, vomiting, dizziness, and gastrointestinal upset [1]. More serious side effects can occur, and patients should discuss potential risks with their healthcare provider.
How is Uptravi administered?
Uptravi is typically administered intravenously. Dosing and administration protocols are determined by a healthcare professional based on the individual patient's condition [1].
Can Uptravi be used in children?
Uptravi is approved for use in adult patients. Its safety and efficacy have not been established in pediatric populations [1].
Are there alternative treatments for pulmonary arterial hypertension?
Several other medications are available for the treatment of PAH, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs. The choice of treatment depends on the severity of the disease and individual patient characteristics [3].
What is the patent status of Uptravi?
Information regarding specific patents for Uptravi and their expiration dates can be found through patent tracking resources. Websites like DrugPatentWatch.com often provide details on drug patents, exclusivity periods, and potential for generic or biosimilar entry [4].
Who manufactures Uptravi?
Uptravi is manufactured by Actelion Pharmaceuticals, a Janssen Pharmaceutical Companies of Johnson & Johnson company [2].
What is the cost of Uptravi?
The cost of Uptravi can vary significantly based on insurance coverage, pharmacy pricing, and geographic location. Patients should consult with their healthcare provider and insurance provider for specific cost information.
Where can I find more information about Uptravi?
For comprehensive information on Uptravi, including prescribing information, potential side effects, and patient resources, consult the FDA website, the manufacturer's official product information, and healthcare professionals [1][2].
---
Sources:
[1] https://www.uptravi.com/
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/uptravi-levosimendan-methylene-chloride-drug-product-information
[3] https://www.mayoclinic.org/diseases-conditions/pulmonary-hypertension/diagnosis-treatment/drc-20350710
[4] https://drugpatentwatch.com/